scholarly journals Clinicopathological characteristics and treatment strategies for young lung cancer patients

2019 ◽  
Vol 7 (5) ◽  
pp. 100-100 ◽  
Author(s):  
Remi Yoneyama ◽  
Hisashi Saji ◽  
Yasufumi Kato ◽  
Yujin Kudo ◽  
Yoshihisa Shimada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Treatment Strategies ◽  
Clinicopathological Characteristics ◽  
Lung Cancer Patients

Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients

2019 ◽  
Vol 21 (10) ◽  
pp. 734-748 ◽  
Author(s):  
Baoling Guo ◽  
Qiuxiang Zheng
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Drug Response ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Cancer Resistance ◽  
Lung Cancer Patients ◽  
Bayes Algorithm

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: The Japanese Lung Cancer Registry Study 2004

Lung Cancer ◽  
2014 ◽  
Vol 83 (2) ◽  
pp. 246-251 ◽  
Author(s):  
Masayoshi Inoue ◽  
Meinoshin Okumura ◽  
Noriyoshi Sawabata ◽  
Etsuo Miyaoka ◽  
Hisao Asamura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Clinicopathological Characteristics ◽  
Surgical Results ◽  
Registry Study ◽  
Lung Cancer Patients

scholarly journals Venous Thromboembolism in Patents With Lung Cancer

2020 ◽  
Vol 26 ◽  
pp. 107602962097791
Author(s):  
Takahito Suzuki ◽  
Susumu Fujino ◽  
Shouta Inaba ◽  
Ryo Yamamura ◽  
Hiromasa Katoh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Cause Of Death ◽  
Clinicopathological Characteristics ◽  
Lung Cancer Patients ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Deep Vein

Lung cancer is the leading cause of death from cancer in Japan. Studies in other countries have reported a venous thromboembolism (VTE) rate of 4%–20% in cancer patients. In this study, we aimed to determine the incidence of VTE in lung cancer patients in Japan and compared the characteristics of patients with and without VTE. In this retrospective cohort study, the clinicopathological characteristics of study patients with and without concomitant VTE were compared. Patients with lung cancer treated at Fukui Prefectural Hospital, Japan from 2008 to 2017. Of the 1471 patients with lung cancer studied, 28 developed VTE. Five patients developed pulmonary thromboembolism (PTE) alone, 9 PTE with concomitant deep vein thrombosis, and 14 deep vein thrombosis alone. Compared with patients in the non-VTE group, the VTE group was significantly younger (mean value ± SD 66.3 ± 10.1 vs. 73.0 ± 10.6 years, p = 0.001), contained significantly more patients with stage IIIb–IV disease (p = 0.002), and had a significantly higher rate of chemotherapy (p < 0.001) and radiation therapy (p = 0.007). There was no significant difference in median survival time from lung cancer diagnosis between the VTE and non-VTE groups. The 1-year mortality rate after VTE diagnosis was 60.7%. Lung cancer was the most frequent cause of death, followed by infection and VTE. Several baseline characteristics differed between patients with and without VTE. The prognosis may worsen after development of VTE, suggesting that lung cancer patients should be carefully monitored for it.

scholarly journals Alteration of Gut Microbiome in Lung Cancer Patients

2019 ◽  
Author(s):  
Li Ming ◽  
Yu Fang ◽  
Chen Xiaohui ◽  
Zhou Huan ◽  
Wei Xiaoqing ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Gut Microbiome ◽  
Treatment Strategies ◽  
Cancer Development ◽  
Healthy Individuals ◽  
Lung Cancer Patients ◽  
Microbial Dysbiosis ◽  
Treatment Naïve ◽  
Immunological Relationship

ABSTRACTLung cancer is the leading cause of cancer death. Better understanding of factors and pathways involved in lung cancer is needed to improve diagnose and treatment strategies. Recent studies have provided insights into the possible correlation between intestinal dysbiosis and cancer development. Although the immunological relationship between gut and lung had been suggested by many researches, however, to date, no study had investigated the characterization of gut microbiome in treatment naïve lung cancer patients, whether it is distinct from that of health individuals and contribute to the onset and development of lung cancer remain unclear. In this study, we investigated whether gut microbiome of lung cancer patients (LC, n=28) is altered compare with that of matched healthy individuals (HC, n=19) by high throughout sequencing of the V3-V4 regions of 16S rDNA in their fecal samples. We also identified microbiota signatures specific for different histological types of lung cancer, including SSC, ADC, and SCLC. The gut microbiome of lung cancer patients is characterized by decreased relative abundance of Prevotella, and increased bacteria groups such as Actinomyces, and Streptococcus, etc. We also detected a mild structural shift in gut microbiome between ADC and SCLC patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals. However, the association between microbial dysbiosis and lung cancer is not clearly understood, future studies involving larger cohorts and metagenomics, or metabolomics, may elucidate the correlations between gut microbiota and lung cancer development.IMPORTANCEThis is the first report to show the alteration of gut microbiome in lung cancer patients. Our results showed that the gut microbiome of lung cancer patients altered significantly compared with healthy individuals.

Sign in / Sign up

Export Citation Format

Share Document